公开(公告)号：US5702672A

公开(公告)日：1997-12-30

申请号：US540512

申请日：1995-10-10

申请人： Sheila H. H. DeWitt ,  Michael Kell ,  Michael R. Pavia ,  John S. Kiely ,  Mel C. Schroeder ,  Charles J. Stankovic ,  Steven Ware

发明人： Sheila H. H. DeWitt ,  Michael Kell ,  Michael R. Pavia ,  John S. Kiely ,  Mel C. Schroeder ,  Charles J. Stankovic ,  Steven Ware

IPC分类号： B01J19/00 ,  C07K1/04 ,  C40B40/06 ,  C40B40/10 ,  C40B50/14 ,  C40B60/14 ,  B01J8/00 ,  C07K17/00 ,  C12M1/00

CPC分类号： C07K1/047 ,  B01J19/0046 ,  C07K1/045 ,  B01J2219/00283 ,  B01J2219/00308 ,  B01J2219/0031 ,  B01J2219/00373 ,  B01J2219/00416 ,  B01J2219/00423 ,  B01J2219/00454 ,  B01J2219/00493 ,  B01J2219/00495 ,  B01J2219/005 ,  B01J2219/00585 ,  B01J2219/0059 ,  B01J2219/00596 ,  B01J2219/00689 ,  B01J2219/00695 ,  B01J2219/0072 ,  B01J2219/00722 ,  B01J2219/00725 ,  C40B40/06 ,  C40B40/10 ,  C40B50/14 ,  C40B60/14

摘要： An apparatus for multiple, simultaneous synthesis of compounds which consists of: a reservoir block having a plurality of wells; a plurality of reaction tubes, usually gas dispersion tubes, having filters on their lower ends; a holder block, having a plurality of apertures; and a manifold, which may have ports to allow introduction/maintenance of a controlled environment. The manifold top wall has apertures and a detachable plate with identical apertures. The apparatus is constructed from materials which will accommodate heating, cooling, agitation, or corrosive reagents. Gaskets are placed between the components. Rods or clamps are provided for fastening the components together. Apparatus operation involves placing the filters on the lower ends of the reaction tubes in the reservoir block wells, and the upper ends passing through the holder block apertures and into the manifold.

摘要翻译： 一种用于多次同时合成化合物的装置，其包括：具有多个孔的储存器块; 多个反应管，通常为气体分散管，在其下端具有过滤器; 具有多个孔的保持器块; 以及可以具有允许引入/维护受控环境的端口的歧管。 歧管顶壁具有孔和具有相同孔的可拆卸板。 该装置由适应加热，冷却，搅拌或腐蚀性试剂的材料构成。 垫片放在组件之间。 提供杆或夹具用于将部件固定在一起。 设备操作涉及将过滤器放置在储存器块井中的反应管的下端，并且通过保持器的上端阻挡孔并进入歧管。

公开(公告)号：US5652146A

公开(公告)日：1997-07-29

申请号：US675863

申请日：1996-07-05

申请人： Michael Kell

发明人： Michael Kell

IPC分类号： A61K49/00 ,  G01N33/15 ,  G01N33/493 ,  G01N33/53 ,  G01N33/70 ,  G01N33/94 ,  G01N33/48

CPC分类号： G01N33/9486 ,  G01N33/493 ,  G06F19/3456 ,  Y10S436/808 ,  Y10S436/816 ,  Y10S436/901 ,  Y10T436/173845

摘要： A method of monitoring compliance of a patient that has been placed on a medication maintenance program with a prescribed medication dosage by determining a normalized urine medication concentration. An unadulterated urine sample is obtained from the patient. The urine medication concentration and urine specific gravity are measured. The normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine and the urine specific gravity. The calculated normalized urine medication concentration is compared with an expected medication concentration value for the patient for the maintenance program prescribed to determine any significant differences therebetween as an indication of noncompliance. Alternatively, a urinary-parameter normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine, the urine specific gravity and at least one selected pharmacokinetic parameter of the medication. The calculated urinary-parameter normalized urine medication concentration is compared with an expected medication concentration value for an average compliant patient for the maintenance program prescribed to determine any significant differences therebetween as an indication of noncompliance.

摘要翻译： 一种通过确定归一化的尿药物浓度来监测已经被放置在药物维持程序上的患者符合规定药物剂量的方法。 从患者获得无搀杂的尿样。 测量尿液药物浓度和尿比重。 根据尿液中测量的药物浓度和尿比重计算标准化尿药浓度。 将计算的标准化尿药浓度与用于维持程序的患者的预期药物浓度值进行比较，以便确定其间的任何显着差异作为不合规的指示。 或者，计算尿参数归一化尿药物浓度作为尿液中测量的药物浓度，尿比重和药物的至少一个选择的药代动力学参数的函数。 将计算的尿参数归一化尿药物浓度与用于平均符合标准的患者的预期药物浓度值进行比较，用于维护程序，用于确定其间的任何显着差异作为不合规的指示。

公开(公告)号：US5908788A

公开(公告)日：1999-06-01

申请号：US697063

申请日：1996-08-19

申请人： Michael Kell

发明人： Michael Kell

IPC分类号： A61K49/00 ,  G01N33/15 ,  G01N33/493 ,  G01N33/53 ,  G01N33/70 ,  G01N33/94 ,  G01N33/48

CPC分类号： G01N33/9486 ,  G01N33/493 ,  G06F19/3456 ,  Y10S436/808 ,  Y10S436/816 ,  Y10S436/901 ,  Y10T436/173845

摘要： A method of monitoring compliance of a patient that has been placed on a medication maintenance program with a prescribed medication dosage by determining a normalized urine methadone concentration. An unadulterated urine sample is obtained from the patient. The urine methadone concentration and urine specific gravity are measured. The normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine and the urine specific gravity. The calculated normalized urine medication concentration is compared with an expected medication concentration value for the patient for the maintenance program prescribed to determine any significant differences therebetween as an indication of noncompliance. Alternatively, a urinary-parameter normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine, the urine specific gravity and at least one selected pharmacokinetic parameter of the medication. The calculated urinary-parameter normalized urine medication concentration is compared with an expected medication concentration value for an average compliant patient for the maintenance program prescribed to determine any significant differences therebetween as an indication of noncompliance.

摘要翻译： 一种通过确定归一化的尿美沙酮浓度来监测已经被放置在药物维持程序上的患者具有规定的药物剂量的顺应性的方法。 从患者获得无搀杂的尿样。 测量尿美沙酮浓度和尿比重。 根据尿液中测量的药物浓度和尿比重计算标准化尿药浓度。 将计算的标准化尿药浓度与用于维持程序的患者的预期药物浓度值进行比较，以便确定其间的任何显着差异作为不合规的指示。 或者，计算尿参数归一化尿药物浓度作为尿液中测量的药物浓度，尿比重和药物的至少一个选择的药代动力学参数的函数。 将计算的尿参数归一化尿药物浓度与用于平均符合标准的患者的预期药物浓度值进行比较，用于维护程序，用于确定其间的任何显着差异作为不合规的指示。

公开(公告)号：US6124136A

公开(公告)日：2000-09-26

申请号：US145821

申请日：1993-11-02

申请人： Michael Kell

发明人： Michael Kell

IPC分类号： A61K49/00 ,  G01N33/15 ,  G01N33/493 ,  G01N33/53 ,  G01N33/70 ,  G01N33/94 ,  G01N33/48

CPC分类号： G01N33/9486 ,  G01N33/493 ,  Y10S436/816 ,  Y10S436/901 ,  Y10T436/173845

摘要： A method of monitoring compliance of a patient that has been placed on a methadone maintenance program by determining plasma methadone concentration from urine methadone concentration. An unadulterated urine sample is obtained from the patient. The urine methadone concentration, pH, and specific gravity are measured. The plasma methadone concentration is calculated as a function of urine methadone concentration, specific gravity, and pH. The calculated plasma methadone concentration is compared with an expected value for the maintenance program prescribed.

摘要翻译： 通过从尿美沙酮浓度确定血浆美沙酮浓度来监测已经放在美沙酮维持程序上的患者的顺应性的方法。 从患者获得无搀杂的尿样。 测量尿美沙酮浓度，pH和比重。 按照美沙酮的浓度，比重和pH值计算血浆美沙酮浓度。 将计算出的等离子体美沙酮浓度与规定的维护计划的预期值进行比较。

公开(公告)号：US5602038A

公开(公告)日：1997-02-11

申请号：US591406

申请日：1996-01-25

申请人： Michael Kell

发明人： Michael Kell

IPC分类号： G01N33/50 ,  G01N33/493 ,  G01N33/70

CPC分类号： G01N33/493 ,  G01N33/70 ,  Y10T436/147777

摘要： In a method of determining creatinine clearance for detecting and monitoring renal dysfunction, spot samples of urine and blood from a person are obtained. Specific gravity or osmolality and creatinine concentration of the urine sample are measured. Creatinine concentration of plasma of the blood sample is also measured. Creatinine clearance is calculated as a function of the measured urine specific gravity or osmolality, the measured urine creatinine concentration and the measured plasma creatinine concentration.

摘要翻译： 在测定用于检测和监测肾功能障碍的肌酐清除率的方法中，获得来自人的尿液和血液的斑点样品。 测量尿液样品的比重或渗透压浓度和肌酐浓度。 还测量血液样品的血浆肌酸酐浓度。 肌酐清除率是根据测得的尿比重或重量摩尔渗透压浓度，测得的尿肌酐浓度和测量的血浆肌酐浓度计算的。

公开(公告)号：US6136801A

公开(公告)日：2000-10-24

申请号：US220533

申请日：1998-12-24

申请人： Michael Kell

发明人： Michael Kell

IPC分类号： G01N33/94 ,  G01N33/48

CPC分类号： G01N33/948 ,  Y10S436/808 ,  Y10S436/901 ,  Y10T436/173845 ,  Y10T436/174614

摘要： Quantitative compliance markers and associated methods for monitoring patient compliance with medication prescriptions associated with compliance markers have been found to eliminate the need for specific quantitative relationships for each new drug tested. Such compliance markers and methods for monitoring patient compliance utilize pharmacologically inert substances, namely the weak acids benzodiazepines, or non-metabolizable substances in association with an underlying drug at a measurable dosage, so as to correlate compliance marker concentration with underlying medication concentration to determine amount of actual medication ingested.

摘要翻译： 已经发现用于监测患者与顺应性标记相关的药物处方的依从性的定量依从性标记和相关方法消除了对于每种新药测试的具体定量关系的需要。 用于监测患者依从性的这种依从性标记和方法利用药理学惰性物质，即弱酸性苯二氮卓类药物或与潜在药物在可测量剂量下相关的不可代谢物质，以便使顺应性标记物浓度与潜在药物浓度相关联以确定量 实际摄取药物。

公开(公告)号：US5955370A

公开(公告)日：1999-09-21

申请号：US888246

申请日：1997-07-07

申请人： Michael Kell

发明人： Michael Kell

IPC分类号： G01N33/15 ,  G01N33/493 ,  G01N33/70 ,  G01N33/94 ,  G01N33/48

CPC分类号： G01N33/948 ,  G01N33/493 ,  G01N33/70 ,  G01N33/94 ,  Y10S436/901 ,  Y10T436/173845

摘要： A test method for determining adulteration by diuresis or the addition of a diuretic, which uses creatinine and specific gravity measurements to determine a normalized creatinine value for comparison with expected normalized creatinine values for the substantially diuretic-free population.

摘要翻译： 用于通过利尿或添加利尿剂来确定掺假的测试方法，其使用肌酐和比重测量法来确定归一化的肌酸酐值，以与基本上不利尿素的人群的预期标准化肌酐值进行比较。

公开(公告)号：US5776783A

公开(公告)日：1998-07-07

申请号：US715016

申请日：1996-09-17

申请人： Michael Kell

发明人： Michael Kell

IPC分类号： G01N33/493 ,  A61K31/515 ,  A61K31/5513 ,  A61K45/00 ,  G01N33/15 ,  G01N33/94 ,  G01N33/48

CPC分类号： G01N33/493 ,  G01N33/94 ,  G01N33/948 ,  Y10S436/808 ,  Y10S436/901 ,  Y10T436/173845

摘要： Quantitative compliance markers and associated methods for monitoring patient compliance with medication prescriptions associated with compliance markers have been found to eliminate the need for specific quantitative relationships for each new drug tested. Such compliance markers and methods for monitoring patient compliance utilize pharmacologically inert substances, namely the weak acids benzodiazepines, or non-metabolizable substances in association with an underlying drug at a measurable dosage, so as to correlate compliance marker concentration with underlying medication concentration to determine amount of actual medication ingested.

摘要翻译： 已经发现用于监测患者与顺应性标记相关的药物处方的依从性的定量依从性标记和相关方法消除了对于每种新药测试的具体定量关系的需要。 用于监测患者依从性的这种依从性标记和方法利用药理学惰性物质，即弱酸性苯二氮卓类药物或与潜在药物在可测量剂量下相关的不可代谢物质，以便使顺应性标记物浓度与潜在药物浓度相关联以确定量 实际摄取药物。

公开(公告)号：US5547878A

公开(公告)日：1996-08-20

申请号：US248102

申请日：1994-05-24

申请人： Michael Kell

发明人： Michael Kell

IPC分类号： G01N33/15 ,  G01N33/493 ,  G01N33/48

CPC分类号： G01N33/493 ,  Y10S436/808 ,  Y10S436/901 ,  Y10T436/173845

摘要： A method of monitoring compliance of a patient that has been placed on a medication maintenance program with a prescribed medication dosage by determining a normalized urine methadone concentration. An unadulterated urine sample is obtained from the patient. The urine methadone concentration and urine specific gravity are measured. The normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine and the urine specific gravity. The calculated normalized urine medication concentration is compared with an expected medication concentration value for the patient for the maintenance program prescribed to determine any significant differences therebetween as an indication of noncompliance.Alternatively, a urinary-parameter normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine, the urine specific gravity and at least one selected pharmacokinetic parameter of the medication. The calculated urinary-parameter normalized urine medication concentration is compared with an expected medication concentration value for an average compliant patient for the maintenance program prescribed to determine any significant differences therebetween as an indication of noncompliance.

公开(公告)号：US5500372A

公开(公告)日：1996-03-19

申请号：US279400

申请日：1994-07-25

申请人： Michael Kell

发明人： Michael Kell

IPC分类号： G01N33/493 ,  G01N33/70 ,  G01N33/50

CPC分类号： G01N33/70 ,  G01N33/493 ,  Y10T436/147777

摘要： In a method of determining creatinine clearance for detecting and monitoring renal dysfunction, spot samples of urine and blood from a person are obtained. Specific gravity and creatinine concentration of the urine sample are measured. Creatinine concentration of plasma of the blood sample is also measured. Creatinine clearance is calculated as a function of the measured urine specific gravity, the measured urine creatinine concentration and the measured plasma creatinine concentration.

摘要翻译： 在测定用于检测和监测肾功能障碍的肌酐清除率的方法中，获得来自人的尿液和血液的斑点样品。 测量尿样的比重和肌酐浓度。 还测量血液样品的血浆肌酸酐浓度。 肌酐清除率作为测量的尿比重，测得的尿肌酐浓度和测量的血浆肌酐浓度的函数计算。